Recent news about the company
«ASYLIA DIAGNOSTICS» IS NOW PART OF MATWIN PROGRAM
Asylia team is now part of MATWIN - EU-leading program entirely dedicated to maturation of innovative companies in oncology.
14 members of MATWIN International Board (out of 17) voted for Asylia!
MATWIN International Board are leading academic, clinical and industrial KOLs in oncology from AstraZeneca, BMS, Novartis, Pfizer, Roche, Amgen, Gilead, Exact Sciences, GSK, BI, Sanofi, Nanostring, Pierre Fabre and other key institutions.
At Asylia we are 100% certain that their expertise will make Asylia’s product bullet-proof strong in scientific, clinical, regulatory and business propositions. Looking forward to work with MATWIN! Thanks for believing in Asylia’s vision, mission and team!